472 related articles for article (PubMed ID: 25389049)
1. Dapagliflozin: a review of its use in patients with type 2 diabetes.
Plosker GL
Drugs; 2014 Dec; 74(18):2191-209. PubMed ID: 25389049
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Plosker GL
Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
[TBL] [Abstract][Full Text] [Related]
3. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
8. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes.
Maranghi M; Carnovale A; Durante C; Tarquini G; Tiseo G; Filetti S
Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):125-37. PubMed ID: 25418019
[TBL] [Abstract][Full Text] [Related]
10. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Shah NK; Deeb WE; Choksi R; Epstein BJ
Pharmacotherapy; 2012 Jan; 32(1):80-94. PubMed ID: 22392830
[TBL] [Abstract][Full Text] [Related]
12. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Leiter LA; Cefalu WT; de Bruin TW; Xu J; Parikh S; Johnsson E; Gause-Nilsson I
Diabetes Obes Metab; 2016 Aug; 18(8):766-74. PubMed ID: 27009868
[TBL] [Abstract][Full Text] [Related]
13. [Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Oct; 71(10):463-469. PubMed ID: 28383856
[TBL] [Abstract][Full Text] [Related]
14. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.
Fioretto P; Giaccari A; Sesti G
Cardiovasc Diabetol; 2015 Oct; 14():142. PubMed ID: 26474563
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM
Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.
Sun YN; Zhou Y; Chen X; Che WS; Leung SW
Syst Rev; 2013 Nov; 2():103. PubMed ID: 24225054
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
